| 中文名 | 8-O-乙酰山栀苷甲酯 |
|---|---|
| 英文名 | methyl (1S,4aS,5R,7S,7aS)-7-acetyloxy-5-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,5,6,7a-tetrahydro-1H-cyclopenta[c]pyran-4-carboxylate |
| 中文别名 |
8-O-乙酰山栀苷甲酯Blerin
巴勒林 8-O-acetyl shanzhiside methyl ester 乙酰山栀苷甲酯,S9244 8-O-乙酰山栀苷甲酯, 来源于独一味 8-O-乙酰山栀苷甲酯,10 MM DMSO 溶液 8-O-乙酰山栀苷甲酯(对照品) 8-O-乙酰山栀苷甲酯(标准品) (1S,4AS,5R,7S,7AS)-7-乙酰氧基-5-羟基-7-甲基-1-(((2S,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-1,4A,5,6,7,7A-六氢环戊并[C]吡喃-4-羧酸甲酯 Blerin8-O-乙酰山栀苷甲酯 8-O-acetyl shanzhiside methyl ester 乙酰山栀苷甲酯,S9244 8-O-ACETYL SHANZHISIDE METHYL ESTER 8-O-乙酰山栀苷甲酯 |
| 英文别名 |
8-acetylshanzhiside methyl ester
8-ortho-acetyl shanzhiside methyl ester 8-O-Acetyl shanzhiside methyl Ac-Shanz-ME 8-Acetylshanzhiside Methyl ester ND01 methyl (1S,4aS,5R,7S,7aS)-7-(acetyloxy)-1-(beta-D-glucopyranosyloxy)-5-hydroxy-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-cboxylate inhibit,Inhibitor,NF-κB,Nuclefactor-κB,Blerin,Nuclefactor-kappaB Methyl (1S,4aS,5R,7S,7aS)-7-acetoxy-1-(β-D-glucopyranosyloxy)-5-hydroxy-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate Barlerin 7α-Acetoxy-1α-(β-D-glucopyranosyloxy)-1,4aα,5,6,7,7aα-hexahydro-5α-hydroxy-7-methylcyclopenta[c]pyran-4-cboxylic acid methyl ester O-Acetyl Shanzhiside Methyl Ester, 8 1α-(β-D-Glucopyranosyloxy)-7α-acetoxy-5α-hydroxy-7-methyl-1,4aα,5,6,7,7aα-hexahydrocyclopenta[c]pyran-4-cboxylic acid methyl ester Cyclopenta[c]pyran-4-cboxylic acid, 7-(acetyloxy)-1-(β-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-5-hydroxy-7-methyl-, methyl ester, (1S,4aS,5R,7S,7aS) Methyl (1S,4aS,5R,7S,7aS)-7-acetoxy-5-hydroxy-7-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-cboxylate Umbroside methyl (1S,4aS,5R,7S,7aS)-7-(acetyloxy)-1-(beta-D-glucopyran UMbroside 8-O-Acetylshanzhiside acetylbarlerin 8-O-Acetyl shanzhiside methyl ester from Lamiophlomis rotata (Benth. ex Hook.f.) Kud ipolamiidoside 8-Acetylshanzhiside methyl ester-RM 8-O-Acetyl shanzhiside methyl ester methyl (1S,4aS,5R,7S,7aS)-7-acetyloxy-5-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,5,6,7a-tetrahydro-1H-cyclopenta[c]pyran-4-cboxylate 8-O-acetylshanziside Blerin (1S)-1α-(β-D-Glucopyranosyloxy)-5α-hydroxy-7α-acetoxy-7-methyl-1,4aα,5,6,7,7aα-hexahydrocyclopenta[c]pyran-4-cboxylic acid methyl ester Blerin, 10 mM in DMSO |
| 描述 | 8-O-Acetyl shanzhiside methyl ester (ND01)是从中国西藏民间药用植物中分离出的环孢菌素葡萄糖苷。8-O-Acetyl shanzhiside methyl ester 可以抑制 NF-κB 活性。 |
|---|---|
| 相关类别 | |
| 靶点 |
NF-κB |
| 体外研究 | 用ND01处理SH-SY5Y细胞阻断TNF-α诱导的核转录因子κB(NF-κB)活化并降低高迁移率族蛋白-1(HMGB-1)的表达。 [1]。用ND019μM处理H9c2细胞通过阻断高迁移率族蛋白1(HMGB1)表达阻断TNF-α诱导的NF-κB磷酸化[2]。 |
| 体内研究 | 即使在I/R后4小时延迟给药,8-O-乙酰基山栀子甲酯40mg/kg也显示出显着的神经保护作用。 8-O-乙酰基山栀子甲酯40 mg/kg可减轻组织病理学损伤,减少脑肿胀,抑制NF-κB活化,降低缺血脑组织中HMGB-1的表达[1]。 8-O-乙酰基山栀子甲酯显着促进缺血性脑中的血管生成,并改善中风后的功能结果。与载体处理相比,8-O-乙酰基山栀子甲酯也显着增加血管形成。它增加VEGF,Ang1的表达,Tie2和Akt VEGF的磷酸化[3]。 8-O-乙酰基山栀子甲酯显着缩短毛细血管凝血时间,减少失血量,但不影响小鼠活化部分凝血活酶时间,凝血酶原时间或凝血酶时间。它显着延长了超纤维蛋白溶解小鼠的优球蛋白凝块溶解时间[4]。 |
| 细胞实验 | 在缺氧之前,用各种浓度(1,3,9和27μM)的ND01预处理细胞24小时。通过MTT测定确定细胞活力[2]。 |
| 动物实验 | 大鼠:在盐水中制备8-O-乙酰基山栀子甲酯。对成年雄性大鼠进行1小时大脑中动脉闭塞(MCAO)和再灌注,并在缺血和再灌注(I / R)后24小时开始,用或不用不同剂量(5和10mg / kg)的ND01治疗。每天静脉注射14天。进行神经功能测试并测量脑伊文思蓝外渗[3]。小鼠:在盐水中制备8-O-乙酰基山栀子甲酯(ASM)。将雄性Balb / C小鼠(20至25g)随机分成5组(生理盐水组,Hemocoagulase,0.34 KU / kg,静脉注射ASM-L,100 mg / kg,静脉注射,ASM-M,250 mg / kg,静脉注射, ASM-H,500mg / kg,iv)。在用戊巴比妥钠(200mg / kg,ip)麻醉前5分钟通过尾静脉注射药物和载体。注射后20分钟,从心脏抽取血液。测定活化的部分促凝血酶原激酶时间,凝血酶原时间,凝血酶时间和纤维蛋白原[4]。 |
| 参考文献 |
| 密度 | 1.52 g/cm3 |
|---|---|
| 沸点 | 634.2±55.0 °C at 760 mmHg |
| 分子式 | C19H28O12 |
| 分子量 | 448.418 |
| 闪点 | 220.0±25.0 °C |
| 精确质量 | 448.158081 |
| PSA | 181.44000 |
| LogP | -2.76 |
| 蒸汽压 | 0.0±4.2 mmHg at 25°C |
| 折射率 | 1.594 |
| 储存条件 | -20°C |
| 安全声明 (欧洲) | 24/25 |
|---|
| 上游产品 0 | |
|---|---|
| 下游产品 1 | |